Halozyme Therapeutics (HALO) Long-Term Deferred Tax (2021 - 2025)
Halozyme Therapeutics (HALO) has disclosed Long-Term Deferred Tax for 5 consecutive years, with $20.2 million as the latest value for Q2 2025.
- Quarterly Long-Term Deferred Tax changed N/A to $20.2 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $20.2 million through Jun 2025, changed N/A year-over-year, with the annual reading at $3.9 million for FY2024, 12.11% down from the prior year.
- Long-Term Deferred Tax for Q2 2025 was $20.2 million at Halozyme Therapeutics, up from $5.2 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $155.4 million in Q4 2021, with the low at $616000.0 in Q1 2024.
- Average Long-Term Deferred Tax over 5 years is $49.3 million, with a median of $22.1 million recorded in 2023.
- The sharpest move saw Long-Term Deferred Tax plummeted 98.27% in 2024, then skyrocketed 742.53% in 2025.
- Over 5 years, Long-Term Deferred Tax stood at $155.4 million in 2021, then crashed by 71.42% to $44.4 million in 2022, then tumbled by 90.13% to $4.4 million in 2023, then fell by 12.11% to $3.9 million in 2024, then soared by 424.2% to $20.2 million in 2025.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $20.2 million, $5.2 million, and $3.9 million for Q2 2025, Q1 2025, and Q4 2024 respectively.